A team of investigators sought to identify the accuracy of diagnostic tools for the detection of nonalcoholic fatty liver disease in adolescent patients.
The American Gastroenterological Association commissioned an expert review to identify best practice advice for treating patients with nonalcoholic fatty liver disease.
Investigators compared a carbohydrate-restricted diet with a low-calorie diet to determine which more effectively reduced hepatic triglyceride content in children with nonalcoholic fatty liver disease.
Investigators studied the risk of overall and cause-specific mortality across the histological spectrum in individuals with non-alcoholic fatty liver disease.
From 2009 to 2018, there was an increase in the incidence of nonalcoholic fatty liver disease among children, although many NAFLD cases remain undiagnosed.
Investigators studied the impact of changes in adiposity over patients’ life courses on the midlife development of nonalcoholic fatty liver disease.
Investigators sought to determine whether a very low-calorie diet is feasible and acceptable to achieve and maintain a weight loss of 10% or more in patients with nonalcoholic fatty liver disease.
The use of CPAP alone does not appear to improve hepatic steatosis and fibrosis in patients with nonalcoholic fatty liver disease and obstructive sleep apnea.
TERN-201 is a highly-selective semicarbazide-sensitive amino oxidase inhibitor.
The NIS4 biomarker panel may provide a means for clinicians to avoid unnecessary liver biopsies in patients at low risk for NASH.
A team of investigators studied the relationship between changes in liver histology and changes in body mass index, dyslipidemia, and measures of glucose homeostasis in children.
A systematic review and meta-analysis of observational studies was conducted to assess the prevalence of nonalcoholic fatty liver disease in the general population.
As the role of the gut microbiome in nonalcoholic fatty liver disease is explored, research has turned to fecal microbiota transplantation as a potential treatment option.
Low thyroid function is associated with nonalcoholic fatty liver disease and predicted all-cause and cardiovascular mortality in this population.
Women with non-alcoholic fatty liver disease have increased risks for maternal and neonatal complications.
First responders to the World Trade Center attacks appear to have a much higher prevalence of hepatic steatosis than the general population.
The FDA has granted Fast Track designation to intravenous choline chloride (Protara Therapeutics), an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease.
Women have a lower overall risk of acquiring nonalcoholic fatty liver disease (NAFLD) than men do, but a higher risk of advanced fibrosis if NAFLD status is confirmed.
The lack of standardized diet and exercise recommendations across NAFLD/NASH clinical trials has posed a significant challenge in understanding their impact.
The first guidelines for assessing the eligibility of patients with NASH for inclusion in clinical studies were released.